TP53 Mutation Analysis in Breast Cancer Samples
Author Information
Author(s): S Gretarsdottir, L Tryggvadottir, JG Jonasson, H Sigurdsson, K Olafsdottir, BA Agnarsson, H Ogmundsdottir, JE Eyfjord
Primary Institution: Icelandic Cancer Society, University Hospital, Reykjavik, Iceland
Hypothesis
Can TP53 mutations be analyzed in archival paraffin-embedded breast carcinoma samples using the CDGE method?
Conclusion
The study found that TP53 mutations can be analyzed in archival breast cancer samples, and those with mutations had a significantly shorter post-recurrence survival.
Supporting Evidence
- TP53 mutations were detected in 30 samples (16.1%) and confirmed by sequencing in 17 cases.
- Immunohistochemistry showed TP53 nuclear accumulation in 58 tumours (31%).
- A strong association between TP53 mutations and immunostaining was observed (P<0.001).
- Patients with abnormal TP53 had a significantly shorter post-recurrence survival (P=0.005).
Takeaway
Researchers looked at old breast cancer samples to see if they had changes in a gene called TP53, which helps control cell growth. They found that some samples had these changes, and patients with them didn't do as well after their cancer came back.
Methodology
DNA was extracted from 193 archival primary breast carcinoma samples, and TP53 mutations were analyzed using constant denaturant gel electrophoresis (CDGE).
Limitations
The study was limited by the quality of DNA from archival samples, which may affect the clarity of results.
Participant Demographics
Median age at diagnosis was 62 years, with a range from 31 to 91 years.
Statistical Information
P-Value
p=0.005
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website